[S02DA03, antipyrine, The metabolism of Ibrutinib can be decreased when combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Streptokinase.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibrutinib.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Ibrutinib.]
[L04AA27, fingolimod, Ibrutinib may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The metabolism of Ibrutinib can be decreased when combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulfinpyrazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ibrutinib.]
[L02BA01, tamoxifen, The metabolism of Ibrutinib can be decreased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Ibrutinib can be decreased when combined with Teniposide.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Ibrutinib can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The metabolism of Ibrutinib can be decreased when combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Ibrutinib can be decreased when combined with Tetracycline.]
[A04AD10, dronabinol, The metabolism of Ibrutinib can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The metabolism of Ibrutinib can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ibrutinib.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Ibrutinib.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Ibrutinib.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Ibrutinib.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Ibrutinib.]
[N05CA19, thiopental, The metabolism of Ibrutinib can be decreased when combined with Thiopental.]
[N05AC02, thioridazine, The metabolism of Ibrutinib can be decreased when combined with Thioridazine.]
[C01BB04, aprindine, The metabolism of Ibrutinib can be decreased when combined with Aprindine.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Ibrutinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Ibrutinib.]
[B01AC05, ticlopidine, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ticlopidine.]
[S01ED01, timolol, The metabolism of Ibrutinib can be decreased when combined with Timolol.]
[N02AX02, tramadol, The metabolism of Ibrutinib can be decreased when combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Trapidil.]
[N06AX05, trazodone, The metabolism of Ibrutinib can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Ibrutinib.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Ibrutinib.]
[N05CD05, triazolam, The metabolism of Ibrutinib can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibrutinib.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Ibrutinib.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Ibrutinib.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Ibrutinib.]
[R06AC04, tripelennamine, The metabolism of Ibrutinib can be decreased when combined with Tripelennamine.]
[J01FA08, troleandomycin, The metabolism of Ibrutinib can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Ibrutinib can be decreased when combined with Vilazodone.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Ibrutinib.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Ibrutinib.]
[L02BX03, abiraterone, The metabolism of Ibrutinib can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Ibrutinib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Ibrutinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Ibrutinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Ibrutinib can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Urokinase.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Ibrutinib.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Rivaroxaban.]
[B01AC24, ticagrelor, The metabolism of Ibrutinib can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Ibrutinib can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Ibrutinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Ibrutinib can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Ibrutinib.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Ibrutinib.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibrutinib.]
[A11HA03, vitamin E, Vitamin E may increase the antiplatelet activities of Ibrutinib.]
[B01AA03, warfarin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Warfarin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Ibrutinib.]
[N05AF05, zuclopenthixol, The metabolism of Ibrutinib can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Ibrutinib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Ibrutinib can be decreased when combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Ibrutinib can be decreased when combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Ibrutinib can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Ibrutinib can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Ibrutinib can be decreased when combined with Rabeprazole.]
[N05AE04, ziprasidone, The metabolism of Ibrutinib can be decreased when combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibrutinib.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ibrutinib.]
[G04BD07, tolterodine, The metabolism of Ibrutinib can be decreased when combined with Tolterodine.]
[C07AB03, atenolol, The metabolism of Ibrutinib can be decreased when combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibrutinib.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Ibrutinib.]
[J02AC03, voriconazole, The metabolism of Ibrutinib can be decreased when combined with Voriconazole.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Ibrutinib.]
[R07AX02, ivacaftor, The metabolism of Ibrutinib can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ibrutinib.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Ibrutinib.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Ibrutinib.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ibrutinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Ibrutinib.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ibrutinib.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib.]
[A08AA11, lorcaserin, The metabolism of Ibrutinib can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Ibrutinib can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Ibrutinib.]
[V03AX03, cobicistat, The metabolism of Ibrutinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Ibrutinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Ibrutinib can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Ibrutinib can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibrutinib.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Defibrotide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Ibrutinib.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Ibrutinib.]
[L01EX05, regorafenib, The metabolism of Ibrutinib can be decreased when combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Ibrutinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ibrutinib.]
[C08CA13, lercanidipine, The metabolism of Ibrutinib can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Ibrutinib can be decreased when combined with Donepezil.]
[N03AX22, perampanel, The metabolism of Ibrutinib can be decreased when combined with Perampanel.]
[L04AA29, tofacitinib, Ibrutinib may increase the immunosuppressive activities of Tofacitinib.]
[G04BD10, darifenacin, The metabolism of Ibrutinib can be decreased when combined with Darifenacin.]
[H01CB05, pasireotide, The metabolism of Ibrutinib can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Ibrutinib can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Ibrutinib.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Ibrutinib can be decreased when combined with Lomitapide.]
[A10BH04, alogliptin, The metabolism of Ibrutinib can be decreased when combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Ibrutinib can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibrutinib.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ibrutinib.]
[G03XC05, ospemifene, The metabolism of Ibrutinib can be decreased when combined with Ospemifene.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Ibrutinib.]
[A06AX06, tegaserod, The metabolism of Ibrutinib can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Ibrutinib.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Ibrutinib can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Ibrutinib can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The metabolism of Ibrutinib can be decreased when combined with Benzatropine.]
[L01EC02, dabrafenib, The metabolism of Ibrutinib can be decreased when combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibrutinib.]
[N06AX28, levomilnacipran, The metabolism of Ibrutinib can be decreased when combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Ibrutinib can be decreased when combined with Bepridil.]
[L03AA14, lipegfilgrastim, Ibrutinib may increase the myelosuppressive activities of Lipegfilgrastim.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Ibrutinib can be decreased when combined with Fusidic acid.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Ibrutinib.]
[J05AP05, simeprevir, The metabolism of Ibrutinib can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Ibrutinib can be decreased when combined with Dapagliflozin.]
[C07AB04, acebutolol, The metabolism of Ibrutinib can be decreased when combined with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Ibrutinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Ibrutinib can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Ibrutinib.]
[S01ED02, betaxolol, The metabolism of Ibrutinib can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Argatroban.]
[L04AC11, siltuximab, The metabolism of Ibrutinib can be decreased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ibrutinib can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Ibrutinib.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Ibrutinib.]
[L01EM01, idelalisib, The metabolism of Ibrutinib can be decreased when combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Peginterferon beta-1a.]
[A16AX10, eliglustat, The metabolism of Ibrutinib can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Ibrutinib can be decreased when combined with Oritavancin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Ibrutinib.]
[N04AA02, biperiden, The metabolism of Ibrutinib can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibrutinib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ibrutinib.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Ibrutinib.]
[L01XK01, olaparib, The metabolism of Ibrutinib can be decreased when combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Ibrutinib can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Ibrutinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Ibrutinib can be decreased when combined with Palbociclib.]
[L01XH03, panobinostat, The metabolism of Ibrutinib can be decreased when combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Ibrutinib.]
[N02BE01, acetaminophen, The metabolism of Ibrutinib can be decreased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Ibrutinib.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Ibrutinib can be decreased when combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Cangrelor.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Ibrutinib.]
[A04AD14, rolapitant, The metabolism of Ibrutinib can be decreased when combined with Rolapitant.]
[S01EC01, acetazolamide, The metabolism of Ibrutinib can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, The metabolism of Ibrutinib can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Ibrutinib.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ibrutinib.]
[J02AC05, isavuconazole, The metabolism of Ibrutinib can be decreased when combined with Isavuconazole.]
[J05AP10, elbasvir, The metabolism of Ibrutinib can be decreased when combined with Elbasvir.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Ibrutinib can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The metabolism of Ibrutinib can be decreased when combined with Bromocriptine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Bupivacaine.]
[C07AA19, bupranolol, The metabolism of Ibrutinib can be decreased when combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Ibrutinib can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, The metabolism of Ibrutinib can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Ibrutinib.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ibrutinib.]
[P01BE02, artemether, The metabolism of Ibrutinib can be decreased when combined with Artemether.]
[M02AA03, clofezone, The metabolism of Ibrutinib can be decreased when combined with Rabeprazole.]
[S01GX07, azelastine, The metabolism of Ibrutinib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Ibrutinib can be decreased when combined with Rucaparib.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ibrutinib can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Ibrutinib.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibrutinib.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Ibrutinib.]
[J05AE09, tipranavir, The metabolism of Ibrutinib can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Ibrutinib.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Ibrutinib.]
[L04AB02, infliximab, The metabolism of Ibrutinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Ibrutinib can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ibrutinib.]
[L04AC14, sarilumab, The metabolism of Ibrutinib can be decreased when combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Ibrutinib can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Ibrutinib.]
[L01XX59, enasidenib, The metabolism of Ibrutinib can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Ibrutinib.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Ibrutinib.]
[J05AG03, efavirenz, The metabolism of Ibrutinib can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Ibrutinib can be decreased when combined with Bopindolol.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibrutinib.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ibrutinib.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibrutinib.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Ibrutinib.]
[C04AX20, buflomedil, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Buflomedil.]
[L01EL02, acalabrutinib, The metabolism of Ibrutinib can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Ibrutinib can be decreased when combined with Letermovir.]
[N01BX04, capsaicin, The metabolism of Ibrutinib can be decreased when combined with Capsaicin.]
[L02BB05, apalutamide, The metabolism of Ibrutinib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Ibrutinib.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ibrutinib.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibrutinib.]
[C07AG02, carvedilol, The metabolism of Ibrutinib can be decreased when combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Ibrutinib can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Ibrutinib can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Baricitinib.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Ibrutinib.]
[C07AB08, celiprolol, The metabolism of Ibrutinib can be decreased when combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Ibrutinib.]
[L01XX62, ivosidenib, The metabolism of Ibrutinib can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Ibrutinib can be decreased when combined with Tafenoquine.]
[N03AX17, stiripentol, The metabolism of Ibrutinib can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Ibrutinib.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Ibrutinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Chloroprocaine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Ibrutinib.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Ibrutinib.]
[L04AA39, emapalumab, The metabolism of Ibrutinib can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Ibrutinib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Ibrutinib can be decreased when combined with Triclabendazole.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Ibrutinib can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Ibrutinib can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Ibrutinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Ibrutinib can be decreased when combined with Alpelisib.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Upadacitinib.]
[L01EJ02, fedratinib, The metabolism of Ibrutinib can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Ibrutinib can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Ibrutinib.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibrutinib.]
[G04BE04, yohimbine, The metabolism of Ibrutinib can be decreased when combined with Yohimbine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Ibrutinib.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Diroximel fumarate.]
[N03AX25, cenobamate, The metabolism of Ibrutinib can be decreased when combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Ibrutinib can be increased when it is combined with Givosiran.]
[R06AB02, dexchlorpheniramine, The metabolism of Ibrutinib can be decreased when combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be decreased when combined with Ibrutinib.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ibrutinib.]
[M01AX21, diacetylrhein, The metabolism of Ibrutinib can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The metabolism of Ibrutinib can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Ibrutinib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Ibrutinib can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Ibrutinib can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Ibrutinib.]
[N02AA08, dihydrocodeine, The metabolism of Ibrutinib can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Ibrutinib can be decreased when combined with Eletriptan.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Ibrutinib.]
[C08CA16, clevidipine, The metabolism of Ibrutinib can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Ibrutinib can be decreased when combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Ibrutinib can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ibrutinib.]
[S03AA08, chloramphenicol, The metabolism of Ibrutinib can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Ibrutinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ibrutinib.]
[G04BD09, trospium, The metabolism of Ibrutinib can be decreased when combined with Trospium.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Ibrutinib is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Ibrutinib.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Ibrutinib.]
[P01BB01, proguanil, The metabolism of Ibrutinib can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Ibrutinib can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Ibrutinib.]
[P01BA01, chloroquine, The metabolism of Ibrutinib can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Ibrutinib can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibrutinib.]
[R06AB04, chlorpheniramine, The metabolism of Ibrutinib can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Ibrutinib can be decreased when combined with Chlorpromazine.]
[M03BB03, chlorzoxazone, The metabolism of Ibrutinib can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Ibrutinib can be decreased when combined with Cholecalciferol.]
[B06AC06, berotralstat, The metabolism of Ibrutinib can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Ibrutinib can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Ibrutinib.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Ibrutinib.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Ibrutinib can be increased when it is combined with Abametapir.]
[G04CB01, finasteride, The metabolism of Ibrutinib can be decreased when combined with Finasteride.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Ibrutinib.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Ibrutinib.]
[R03CC15, formoterol, The metabolism of Ibrutinib can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibrutinib.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib.]
[A02BA01, cimetidine, The metabolism of Ibrutinib can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Ibrutinib can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Ibrutinib can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Ibrutinib can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ibrutinib.]
[N06AB04, citalopram, The metabolism of Ibrutinib can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Ibrutinib can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Anifrolumab.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Ibrutinib.]
[R06AA04, clemastine, The metabolism of Ibrutinib can be decreased when combined with Clemastine.]
[J01FF01, clindamycin, The metabolism of Ibrutinib can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Ibrutinib can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The metabolism of Ibrutinib can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Ibrutinib.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Ibrutinib.]
[C01EB24, mavacamten, The serum concentration of Ibrutinib can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Ibrutinib.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Ibrutinib can be decreased when combined with Ondansetron.]
[L01XX77, adagrasib, The serum concentration of Ibrutinib can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Ibrutinib can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Ibrutinib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Ibrutinib can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Ibrutinib can be decreased when combined with Codeine.]
[M04AC01, colchicine, The metabolism of Ibrutinib can be decreased when combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Ibrutinib can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Ibrutinib.]
[J01FA15, telithromycin, The metabolism of Ibrutinib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ibrutinib.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Indobufen.]
[N02CC05, almotriptan, The metabolism of Ibrutinib can be decreased when combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Ibrutinib can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Bemiparin.]
[N05BA10, ketazolam, The metabolism of Ibrutinib can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The metabolism of Ibrutinib can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Ibrutinib can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ibrutinib.]
[S01BA03, cortisone, The metabolism of Ibrutinib can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The metabolism of Ibrutinib can be decreased when combined with Lofexidine.]
[C08CA11, manidipine, The metabolism of Ibrutinib can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Ibrutinib.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Ibrutinib can be decreased when combined with Mequitazine.]
[C03DA04, eplerenone, The metabolism of Ibrutinib can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, The metabolism of Ibrutinib can be decreased when combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Ibrutinib.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibrutinib.]
[J01FA03, midecamycin, The metabolism of Ibrutinib can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Ibrutinib.]
[N06AX07, minaprine, The metabolism of Ibrutinib can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, Ibrutinib may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Ibrutinib can be decreased when combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Ibrutinib can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Ibrutinib can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Ibrutinib can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ibrutinib.]
[G04BE09, vardenafil, The metabolism of Ibrutinib can be decreased when combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Ibrutinib can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ibrutinib.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ibrutinib.]
[G03XA01, danazol, The metabolism of Ibrutinib can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Ibrutinib can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Ibrutinib can be decreased when combined with Daunorubicin.]
[C02CC04, debrisoquin, The metabolism of Ibrutinib can be decreased when combined with Debrisoquine.]
[C07AB12, nebivolol, The metabolism of Ibrutinib can be decreased when combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Ibrutinib can be decreased when combined with Nefazodone.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Fondaparinux.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib.]
[N06AB10, escitalopram, The serum concentration of Ibrutinib can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Ibrutinib can be decreased when combined with Solifenacin.]
[N06AA01, desipramine, The metabolism of Ibrutinib can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ibrutinib.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ibrutinib.]
[N03AF02, oxcarbazepine, The metabolism of Ibrutinib can be decreased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Ibrutinib can be decreased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Ibrutinib can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Ibrutinib can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Ibrutinib can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Ibrutinib can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Ibrutinib can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Ibrutinib can be decreased when combined with Dextromethorphan.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ibrutinib.]
[N06AB05, paroxetine, The metabolism of Ibrutinib can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel.]
[A03AX15, peppermint oil, The metabolism of Ibrutinib can be decreased when combined with Peppermint oil.]
[N05BA01, diazepam, The metabolism of Ibrutinib can be decreased when combined with Diazepam.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Cinchocaine.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ibrutinib.]
[L01EB02, erlotinib, The metabolism of Ibrutinib can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Ibrutinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Ibrutinib can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Difluocortolone.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibrutinib.]
[N02CA01, dihydroergotamine, The metabolism of Ibrutinib can be decreased when combined with Dihydroergotamine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ibrutinib.]
[J05AE08, atazanavir, The metabolism of Ibrutinib can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ibrutinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Ibrutinib can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Ibrutinib can be decreased when combined with Dimethyl sulfoxide.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Ibrutinib can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Ibrutinib.]
[N05AL04, remoxipride, The metabolism of Ibrutinib can be decreased when combined with Remoxipride.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Ibrutinib can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Ibrutinib can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ibrutinib can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The metabolism of Ibrutinib can be decreased when combined with Risperidone.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibrutinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Ibrutinib can be decreased when combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Ibrutinib can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Ibrutinib.]
[G04BE08, tadalafil, The metabolism of Ibrutinib can be decreased when combined with Tadalafil.]
[C02KX02, ambrisentan, The metabolism of Ibrutinib can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ibrutinib can be decreased when combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Ibrutinib can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ibrutinib.]
[A03FA03, domperidone, The metabolism of Ibrutinib can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Ibrutinib can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Ibrutinib can be decreased when combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Ibrutinib can be decreased when combined with Doxorubicin.]
[N06AB06, sertraline, The metabolism of Ibrutinib can be decreased when combined with Sertraline.]
[C10AA01, simvastatin, The metabolism of Ibrutinib can be decreased when combined with Simvastatin.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Ibrutinib.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Ibrutinib.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Ibrutinib.]
[D01BA02, terbinafine, The metabolism of Ibrutinib can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Ibrutinib.]
[G01AF08, tioconazole, The metabolism of Ibrutinib can be decreased when combined with Tioconazole.]
[N05BA23, tofisopam, The metabolism of Ibrutinib can be decreased when combined with Tofisopam.]
[N06BA09, atomoxetine, The metabolism of Ibrutinib can be decreased when combined with Atomoxetine.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Triflusal.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Ibrutinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Troxerutin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ibrutinib.]
[S01GX10, epinastine, The metabolism of Ibrutinib can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Ibrutinib can be decreased when combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Ibrutinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Ibrutinib can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Ibrutinib.]
[N05CF02, zolpidem, The metabolism of Ibrutinib can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The metabolism of Ibrutinib can be decreased when combined with Zonisamide.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ibrutinib.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost.]
[N02CA02, ergotamine, The metabolism of Ibrutinib can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Ibrutinib can be decreased when combined with Erythromycin.]
[H05BX01, cinacalcet, The metabolism of Ibrutinib can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Ibrutinib can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Ibrutinib.]
[J04AK02, ethambutol, The metabolism of Ibrutinib can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Ibrutinib can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Ibrutinib can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Ibrutinib can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Ibrutinib can be decreased when combined with Ethinylestradiol.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ibrutinib can be decreased when combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Ibrutinib can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The metabolism of Ibrutinib can be decreased when combined with Sertindole.]
[L04AD02, tacrolimus, The metabolism of Ibrutinib can be decreased when combined with Tacrolimus.]
[R06AX11, astemizole, The metabolism of Ibrutinib can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Ibrutinib can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Ibrutinib can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Ibrutinib can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Ibrutinib can be decreased when combined with Encainide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Ibrutinib.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dextran.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ibrutinib.]
[C08CA02, felodipine, The metabolism of Ibrutinib can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The metabolism of Ibrutinib can be decreased when combined with Fenfluramine.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Ibrutinib.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Ibrutinib.]
[N07AX03, cevimeline, The metabolism of Ibrutinib can be decreased when combined with Cevimeline.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Ibrutinib.]
[J02AC01, fluconazole, The metabolism of Ibrutinib can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Ibrutinib.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ibrutinib.]
[N07CA03, flunarizine, The metabolism of Ibrutinib can be decreased when combined with Flunarizine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ibrutinib.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ibrutinib.]
[V03AZ01, ethanol, The metabolism of Ibrutinib can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Ibrutinib.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ibrutinib.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ibrutinib.]
[N06AB03, fluoxetine, The serum concentration of Ibrutinib can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ibrutinib.]
[N05AB02, fluphenazine, The metabolism of Ibrutinib can be decreased when combined with Fluphenazine.]
[L02BB01, flutamide, The metabolism of Ibrutinib can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ibrutinib.]
[J05AE10, darunavir, The metabolism of Ibrutinib can be decreased when combined with Darunavir.]
[N06DA04, galantamine, The metabolism of Ibrutinib can be decreased when combined with Galantamine.]
[L01EA02, dasatinib, The metabolism of Ibrutinib can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Ibrutinib can be decreased when combined with Cabergoline.]
[N01AH02, alfentanil, The metabolism of Ibrutinib can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Ibrutinib can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Ibrutinib can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, The metabolism of Ibrutinib can be decreased when combined with Dexmedetomidine.]
[C02CA04, doxazosin, The metabolism of Ibrutinib can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ibrutinib.]
[L01EX02, sorafenib, The metabolism of Ibrutinib can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The metabolism of Ibrutinib can be decreased when combined with Esmolol.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Fluindione.]
[P01BX01, halofantrine, The metabolism of Ibrutinib can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The metabolism of Ibrutinib can be decreased when combined with Haloperidol.]
[N05AH04, quetiapine, The metabolism of Ibrutinib can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ibrutinib.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibrutinib.]
[C09CA01, losartan, The metabolism of Ibrutinib can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Heparin.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Ibrutinib.]
[J05AG01, nevirapine, The metabolism of Ibrutinib can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Ibrutinib can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.]
[C02DB02, hydralazine, The metabolism of Ibrutinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Ibrutinib.]
[S02BA01, hydrocortisone, The metabolism of Ibrutinib can be decreased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Ibrutinib.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ibrutinib.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ibrutinib.]
[N05BB01, hydroxyzine, The metabolism of Ibrutinib can be decreased when combined with Hydroxyzine.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Ibrutinib.]
[L01AA06, ifosfamide, The metabolism of Ibrutinib can be decreased when combined with Ifosfamide.]
[N06AA02, imipramine, The metabolism of Ibrutinib can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Ibrutinib.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Tixocortol.]
[L01CE01, topotecan, The metabolism of Ibrutinib can be decreased when combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibrutinib.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ibrutinib.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ibrutinib.]
[N06AX17, milnacipran, The metabolism of Ibrutinib can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Ibrutinib.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Articaine.]
[N05BA12, alprazolam, The metabolism of Ibrutinib can be decreased when combined with Alprazolam.]
[C10AA06, cerivastatin, The metabolism of Ibrutinib can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Anagrelide.]
[C07AA01, alprenolol, The metabolism of Ibrutinib can be decreased when combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibrutinib.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Ibrutinib.]
[N06AF05, iproniazid, The metabolism of Ibrutinib can be decreased when combined with Iproniazid.]
[N04BX02, entacapone, The metabolism of Ibrutinib can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Ibrutinib can be decreased when combined with Isoniazid.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Bivalirudin.]
[N06AX18, reboxetine, The metabolism of Ibrutinib can be decreased when combined with Reboxetine.]
[L04AC07, tocilizumab, The metabolism of Ibrutinib can be increased when combined with Tocilizumab.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Ibrutinib can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Ibrutinib can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Ibrutinib can be decreased when combined with Olanzapine.]
[L04AA24, abatacept, The metabolism of Ibrutinib can be increased when combined with Abatacept.]
[N04BC09, rotigotine, The metabolism of Ibrutinib can be decreased when combined with Rotigotine.]
[C07AG01, labetalol, The metabolism of Ibrutinib can be decreased when combined with Labetalol.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Ibrutinib.]
[G03AD01, levonorgestrel, The metabolism of Ibrutinib can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Ibrutinib can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The metabolism of Ibrutinib can be decreased when combined with Lisuride.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Ibrutinib.]
[C10AA02, lovastatin, The metabolism of Ibrutinib can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Ibrutinib.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ibrutinib.]
[L01EA03, nilotinib, The metabolism of Ibrutinib can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The metabolism of Ibrutinib can be decreased when combined with Maprotiline.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ibrutinib.]
[R06AE05, meclizine, The metabolism of Ibrutinib can be decreased when combined with Meclizine.]
[P01BC02, mefloquine, The metabolism of Ibrutinib can be decreased when combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Ibrutinib.]
[N03AB04, mephenytoin, The metabolism of Ibrutinib can be decreased when combined with Mephenytoin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Mepivacaine.]
[N05AC03, mesoridazine, The metabolism of Ibrutinib can be decreased when combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Ibrutinib can be decreased when combined with Paliperidone.]
[A04AA04, dolasetron, The metabolism of Ibrutinib can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Ibrutinib can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Ibrutinib can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The metabolism of Ibrutinib can be decreased when combined with Metamfetamine.]
[H03BB02, methimazole, The metabolism of Ibrutinib can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ibrutinib.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Ibrutinib.]
[N05AA02, methotrimeprazine, The metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.]
[N02BG09, methoxyflurane, The metabolism of Ibrutinib can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibrutinib.]
[V04CG05, methylene blue, The metabolism of Ibrutinib can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Ibrutinib can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ibrutinib.]
[A03FA01, metoclopramide, The metabolism of Ibrutinib can be decreased when combined with Metoclopramide.]
[C07AB02, metoprolol, The metabolism of Ibrutinib can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Ibrutinib can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Ibrutinib can be decreased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Ibrutinib can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Ibrutinib can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Ibrutinib can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Ibrutinib can be decreased when combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Parnaparin.]
[N05CD08, midazolam, The metabolism of Ibrutinib can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The metabolism of Ibrutinib can be decreased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tinzaparin.]
[L01XX23, mitotane, The metabolism of Ibrutinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ibrutinib.]
[N06BA12, lisdexamfetamine, The metabolism of Ibrutinib can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, The metabolism of Ibrutinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Ibrutinib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Ibrutinib.]
[A04AA05, palonosetron, The metabolism of Ibrutinib can be decreased when combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Ibrutinib can be increased when combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ibrutinib.]
[L01EX03, pazopanib, The metabolism of Ibrutinib can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibrutinib.]
[G03XC01, raloxifene, The metabolism of Ibrutinib can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Ibrutinib.]
[N03AB05, fosphenytoin, The metabolism of Ibrutinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibrutinib.]
[C07AA12, nadolol, The metabolism of Ibrutinib can be decreased when combined with Nadolol.]
[V03AB15, naloxone, The metabolism of Ibrutinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Ibrutinib can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Ibrutinib can be decreased when combined with Amphetamine.]
[A10BG01, troglitazone, The metabolism of Ibrutinib can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Ibrutinib can be decreased when combined with Duloxetine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ibrutinib.]
[L01CD02, docetaxel, The metabolism of Ibrutinib can be decreased when combined with Docetaxel.]
[B01AC17, tirofiban, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Tirofiban.]
[N05AX14, iloperidone, The metabolism of Ibrutinib can be decreased when combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Ibrutinib can be decreased when combined with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Ibrutinib.]
[C10AD02, niacin, The metabolism of Ibrutinib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Ibrutinib can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Ibrutinib can be decreased when combined with Nicergoline.]
[C08CA05, nifedipine, The metabolism of Ibrutinib can be decreased when combined with Nifedipine.]
[C08CA07, nisoldipine, The metabolism of Ibrutinib can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Ibrutinib can be decreased when combined with Nitrendipine.]
[R07AX01, nitric oxide, The metabolism of Ibrutinib can be decreased when combined with Nitric Oxide.]
[N05CF03, zaleplon, The metabolism of Ibrutinib can be decreased when combined with Zaleplon.]
[G03DC02, norethindrone, The metabolism of Ibrutinib can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The metabolism of Ibrutinib can be decreased when combined with Norfloxacin.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Ibrutinib.]
[R05DA07, noscapine, The metabolism of Ibrutinib can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reviparin.]
[H01CB02, octreotide, The metabolism of Ibrutinib can be decreased when combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Ibrutinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Ibrutinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Ibrutinib can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Ibrutinib.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Ancrod.]
[G04CA02, tamsulosin, The metabolism of Ibrutinib can be decreased when combined with Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Ibrutinib can be decreased when combined with Oxamniquine.]
[C07AA02, oxprenolol, The metabolism of Ibrutinib can be decreased when combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Ibrutinib can be decreased when combined with Oxycodone.]
[A14AA05, oxymetholone, The metabolism of Ibrutinib can be decreased when combined with Oxymetholone.]
[N02AA11, oxymorphone, The metabolism of Ibrutinib can be decreased when combined with Oxymorphone.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Danaparoid.]
[H02AB05, paramethasone, The metabolism of Ibrutinib can be decreased when combined with Paramethasone.]
[G04BD11, fesoterodine, The metabolism of Ibrutinib can be decreased when combined with Fesoterodine.]
[C07AA23, penbutolol, The metabolism of Ibrutinib can be decreased when combined with Penbutolol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Ibrutinib.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib.]
[N05CA01, pentobarbital, The metabolism of Ibrutinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Ibrutinib.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentoxifylline.]
[C08EX02, perhexiline, The metabolism of Ibrutinib can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Ibrutinib can be decreased when combined with Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibrutinib.]
[N02BE03, phenacetin, The metabolism of Ibrutinib can be decreased when combined with Phenacetin.]
[N06AF03, phenelzine, The metabolism of Ibrutinib can be decreased when combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Ibrutinib can be decreased when combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Ibrutinib can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Phenprocoumon.]
[N03AB02, phenytoin, The metabolism of Ibrutinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Ibrutinib can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Ibrutinib can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The metabolism of Ibrutinib can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Ibrutinib can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Ibrutinib can be decreased when combined with Pimozide.]
[C07AA03, pindolol, The metabolism of Ibrutinib can be decreased when combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Ibrutinib can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The metabolism of Ibrutinib can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Ibrutinib can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Ibrutinib can be decreased when combined with Pipotiazine.]
[J05AG02, delavirdine, The metabolism of Ibrutinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Ibrutinib can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Alteplase.]
[L04AC08, canakinumab, The metabolism of Ibrutinib can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibrutinib.]
[J05AE03, ritonavir, The serum concentration of Ibrutinib can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Ibrutinib can be decreased when combined with Saxagliptin.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ibrutinib.]
[C07AB01, practolol, The metabolism of Ibrutinib can be decreased when combined with Practolol.]
[P02BA01, praziquantel, The metabolism of Ibrutinib can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Ibrutinib.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Ibrutinib.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Ibrutinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Ibrutinib can be increased when combined with Primidone.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Ibrutinib.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Ibrutinib.]
[N05AB04, prochlorperazine, The metabolism of Ibrutinib can be decreased when combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Ibrutinib can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Ibrutinib can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Ibrutinib can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Ibrutinib can be decreased when combined with Propafenone.]
[L01XH02, romidepsin, The metabolism of Ibrutinib can be decreased when combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Ibrutinib can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Ibrutinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Ibrutinib can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ibrutinib.]
[B01AC09, epoprostenol, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Epoprostenol.]
[N05AX12, aripiprazole, The metabolism of Ibrutinib can be decreased when combined with Aripiprazole.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ibrutinib.]
[R06AC01, pyrilamine, The metabolism of Ibrutinib can be decreased when combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Ibrutinib can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The metabolism of Ibrutinib can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Ibrutinib can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Ibrutinib can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The metabolism of Ibrutinib can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Ibrutinib can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Ibrutinib can be decreased when combined with Roxithromycin.]
[C05CA01, rutin, The metabolism of Ibrutinib can be decreased when combined with Rutin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibrutinib.]
[N04BD01, selegiline, The metabolism of Ibrutinib can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ibrutinib.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Ibrutinib.]
[H01CB01, somatostatin, The metabolism of Ibrutinib can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Ibrutinib.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Ibrutinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibrutinib.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Ibrutinib.]
[N03AG01, valproic acid, The metabolism of Ibrutinib can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydrocortisone butyrate.]
